BLAINTRAVENOUSVIAL
Approved
Jul 2002
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
15
Data completeness
5/8 — Partial
ELITEK (rasburicase) by Sanofi is humans, uric acid is the final step in the catabolic pathway of purines. First approved in 2002.
Drug data last refreshed 3h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ELITEK (rasburicase) is a recombinant uricase enzyme administered intravenously that catalyzes the oxidation of uric acid to allantoin, a more soluble and readily excreted metabolite. It is used to manage hyperuricemia and prevent or treat tumor lysis syndrome in patients with hematologic malignancies at risk of rapid cell death. The drug converts poorly soluble uric acid into an inactive compound, reducing nephrotoxicity and associated complications.
$0.571MPart D
LOE ApproachingLate-stage lifecycle with modest Part D utilization (63 claims in 2023) signals a contracted commercial team focused on retention and managed-care relationships.
Mechanism of Action
humans, uric acid is the final step in the catabolic pathway of purines. Rasburicase catalyzes enzymatic oxidation of poorly soluble uric acid into an inactive and more soluble metabolite (allantoin).
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (15)
MIELITEKO Lifestyle Intervention Study
Started Aug 2022
Evaluate the Efficacy and Safety of Rasburicase (Fasturtec®) in the Prevention and Treatment of Hyperuricemia in Pediatric Patients With Non-Hodgkin's Lymphoma and Acute Leukemia
Started May 2020
50 enrolled
Lymphoma
Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2
Started Apr 2011
55 enrolled
LeukemiaLymphoma
Elitek (Rasburicase) Immuno-Monitoring Study
Started Feb 2010
1 enrolled
Tumor Lysis Syndrome
Rasburicase in Patients at Risk for Tumor Lysis Syndrome
Started Jan 2008
82 enrolled
Tumor Lysis Syndrome
Worked on ELITEK at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.